CIK 0001761612 · Non-accelerated filer<br>Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 011441223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-14 | Lee Kevin Chief Executive Officer | Sale | −2,642 | $32.93 | $87K | 256,908 |
| 2021-07-14 | Lee Kevin Chief Executive Officer | Sale | −2,686 | $33.85 | $91K | 254,222 |
| 2021-07-14 | Lee Kevin Chief Executive Officer | Sale | −9,084 | $34.89 | $317K | 245,138 |
| 2021-07-14 | Lee Kevin Chief Executive Officer | Sale | −53 | $35.16 | $2K | 245,085 |
| 2021-07-14 | Lee Kevin Chief Executive Officer | Option exercise · Stock Option (right to buy) | −8,331 | 368,831 | ||
| 2021-07-13 | BINGHAM KATE Director | Sale | −588 | $33.50 | $20K | 1,875,049 |
| 2021-07-13 | BINGHAM KATE Director | Sale | −12 | $33.50 | $402 | 39,625 |
| 2021-07-13 | BINGHAM KATE Director | Sale | −588 | $33.50 | $20K | 1,875,049 |
| 2021-07-13 | BINGHAM KATE Director | Sale | −12 | $33.50 | $402 | 39,625 |
| 2021-07-13 | Crockett Nigel Chief Business Officer | Option exercise | +40,426 | $11.66 | $471K | 40,426 |
| 2021-07-13 | Crockett Nigel Chief Business Officer | Option exercise | +19,256 | $9.82 | $189K | 59,682 |
| 2021-07-13 | Crockett Nigel Chief Business Officer | Option exercise | +13,019 | $15.36 | $200K | 72,701 |
| 2021-07-13 | Crockett Nigel Chief Business Officer | Sale | −69,580 | $32.41 | $2.3M | 3,121 |
| 2021-07-13 | Crockett Nigel Chief Business Officer | Sale | −3,121 | $33.09 | $103K | 0 |
| 2021-07-13 | Crockett Nigel Chief Business Officer | Option exercise · Employee Stock Option (right to buy) | −40,426 | 62,660 | ||
| 2021-07-13 | Crockett Nigel Chief Business Officer | Option exercise · Employee Stock Option (right to buy) | −19,256 | 38,750 | ||
| 2021-07-13 | Crockett Nigel Chief Business Officer | Option exercise · Employee Stock Option (right to buy) | −13,019 | 30,764 | ||
| 2021-07-13 | Lee Kevin Chief Executive Officer | Option exercise | +35,446 | $14.00 | $496K | 290,180 |
| 2021-07-13 | Lee Kevin Chief Executive Officer | Sale | −21,979 | $32.42 | $713K | 268,201 |
| 2021-07-13 | Lee Kevin Chief Executive Officer | Sale | −5,788 | $33.09 | $192K | 262,413 |
Page 22 of 26 · 520 trades